Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- DSP Completes Acquisition of BBI, Bolsters Oncology Business
April 27, 2012
- Boehringer Ingelheim to Shift to Independent Marketing in Japan for Upcoming New Products
April 27, 2012
- Seikagaku Terminates Agreement with Finland’s Biotie
April 26, 2012
- Latuda Shows Usefulness for Bipolar I Depression in 2 PIII Clinical Trials: DSP
April 26, 2012
- R-Tech Ueno Completes PI Study for Treatment of Hypotrichosis of the Eyelashes
April 26, 2012
- New COPD Treatment Meets Primary Endpoints in Fourth PIII Trial: Sosei Group
April 26, 2012
- Hisamitsu Fails to Obtain Expected Results in Domestic PIII Study for Tinea Unguium Treatment
April 26, 2012
- Takeda Launches Renal Anemia Drug Omontys in US
April 26, 2012
- 50% of Doctors Obtain Information on New Drugs From MRs: Survey
April 25, 2012
- Generics Aimed for Early Stage Sales of 10 Billion Yen, in the Black for Establishing Base: Daiichi Sankyo Espha President Yoshiwaka
April 25, 2012
- Fujifilm Finechemicals’ New Factory in Fukushima Goes Online April 25
April 25, 2012
- Ono Upwardly Revises Profit Forecasts for FY2011
April 25, 2012
- Hyperphosphatemia Treatment JTT-751 Demonstrates Non-Inferiority in PIII Study: JT, Torii
April 25, 2012
- Senju to Launch Strategic Product Aiphagan in May, Expecting Efficacy in Maintaining Field of Vision
April 24, 2012
- Astellas Senior VP Sato Shares Plans to Market Gonax Within Current Structure, MRs Dedicated to Cancer “a Future Issue”
April 24, 2012
- Wakamoto’s New Midterm Business Plan Calls for Operating, Ordinary Profits in Fiscal Year Ending March 2013
April 24, 2012
- Daiichi Sankyo to Market Ranbaxy Products in China
April 24, 2012
- Bayer Yakuhin to Set Up Committee to Promote Proper Use of Xarelto
April 23, 2012
- TPU Withdraws NDA for Aricept Transdermal Patch: Eisai
April 23, 2012
- Terapia Ranbaxy to Launch Fixed Dose Combination of Olmesartan, Amlodipine in Romania
April 23, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…